MG
SYRS

Marex Group’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Marex Group’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-16,700
Closed -$3.84K – 886
2024
Q4 		$3.84K Buy
16,700
+4,000
+31% +$4.8K ﹤0.01% 669
2024
Q3 		$27.3K Buy
+12,700
New +$45.6K ﹤0.01% 575

Other funds holding SYRS

Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BBA
Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return
1CM
1492 Capital Management Milwaukee, Wisconsin $263M AUM 61.9% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Marex Group's SYRS Position: Q1 2025 in Review

Marex Group sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2025, closing a stake of 16,700 shares — an estimated $3.84K sold.

Marex Group first reported a position in SYRS in Q3 2024 and held it in 2 quarters. The position peaked at $27.3K in Q3 2024. 7 funds tracked by Wall St. Rank hold SYRS as of Q1 2025.

  • Marex Group reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q1 2025 after selling out during the quarter.
  • Marex Group sold 16,700 Syros Pharmaceuticals, Inc. Common Stock shares in Q1 2025, an estimated $3.84K.
  • Marex Group first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q3 2024 and held it in 2 quarters.
  • Marex Group's Syros Pharmaceuticals, Inc. Common Stock position peaked at $27.3K in Q3 2024.
  • 7 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2025.

Based on Marex Group's 13F filing for Q1 2025, filed 2 Apr 2026.